PROF · Profound Medical Corp.
$6.85
+0.07 (+1.03%)
At close · Jul 17
Market Cap
$248.91M
Shares
36.34M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$16.1M
+50.7%
FY2025
Net Income
-$42.57M
-53%
FY2025
Gross Margin
70.77%
+4.9pp
FY2025
Operating Margin
-256.27%
+53.3pp
FY2025
Diluted EPS
$1.41
+25.9%
FY2025
Operating Cash Flow
-$38.21M
-62.9%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|---|
| $25M | $18.81M | $16.1M | $10.68M | $7.2M | |
| — | $890K | — | $940K | $1.3M | |
| — | $5.44M | $4.71M | $3.64M | $2.89M | |
| — | $13.37M | $11.39M | $7.04M | $4.31M | |
| — | — | 70.77% | 65.89% | 59.9% | |
| — | $21.05M | $20.6M | $16.97M | $14.42M | |
| — | $30.43M | $32.05M | $23.13M | $18.54M | |
| — | — | $187K | $229K | $202K | |
| — | $51.48M | $52.65M | $40.1M | $32.96M | |
| — | -$38.11M | -$41.25M | -$33.06M | -$28.65M | |
| — | — | -256.27% | -309.57% | -397.99% | |
| — | -$554K | -$1.06M | $5.24M | $200K | |
| — | -$38.66M | -$42.32M | -$27.82M | -$28.45M | |
| — | $236K | $252K | -$2000 | -$128K | |
| — | -$38.9M | -$42.57M | -$27.82M | -$28.32M | |
| — | — | -264.44% | -260.45% | -393.43% | |
| — | $38.9M | $42.57M | $27.82M | — | |
| — | -$37.72M | -$40.29M | -$30.64M | -$27.68M | |
| USD/shares | — | — | $1.41 | $1.12 | $1.34 |
| USD/shares | — | — | $1.41 | $1.12 | $1.34 |
| shares | — | — | 30.23M | 24.77M | 21.18M |
| shares | — | — | 30.23M | 24.77M | 21.18M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Medical Devices median 2.19×
EV/EBIT
—
Medical Devices median 21.32×
P/E (TTM)
5.52×
Medical Devices median 27.98×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| United States | $12,245,000 | $7,350,000 | $5,126,000 |
| Canada | $3,080,000 | $2,439,000 | — |
| Germany | $773,000 | $891,000 | — |
| CA | — | — | $230,000 |
| DE | — | — | $1,843,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Recurring Non-Capital | $9,730,000 | $8,240,000 | $6,806,000 |
| Capital Equipment | $6,368,000 | $2,440,000 | $393,000 |